810685-49-5

Upstream product

• 3457-46-3 4,4'-dichlorobenzil 
• 4254-20-0 4,4'-dichlorobenzoin 
• 104-88-1 4-chlorobenzaldehyde 
• 810685-47-3 5,6-bis(4-chlorophenyl)-pyrazine-2,3-dicarbonitrile 

Downstream Products

• 810685-50-8 2,3-bis(4-chlorophenyl)furo[3.4-b]pyrazine-5,7-dione 
• 810685-51-9 5,6-bis(4-chlorophenyl)-3-(piperidin-1-ylcarbonyl)pyrazine-2-carboxylic acid 
• 810685-52-0 5,6-bis(4-chlorophenyl)-N-piperidin-1-yl-3-(piperidin-1-ylcarbonyl)pyrazine-2-carboxamide 
• 811436-91-6 5,6-bis(4-chlorophenyl)-3-(4-methyl-4,5-dihydrooxazol-2-yl)-pyrazine-2-carboxylic acid tert-butyl ester 
• 811436-88-1 5,6-bis(4-chlorophenyl)-3-(tert-butoxycarbonyl)-pyrazine-2-carboxylic acid 

Relevant academic research and scientific papers

THERAPEUTIC AGENTS

The present invention relates to compounds of formula (I); and pharmaceutically acceptable salts thereof, in which R1 and R2 independently represent phenyl, thienyl, pyridyl, C1-10alkyl, C1-10alkoxy or C3-1

5,6-BIS (4-CHLOROPHENYL)-N-PIPERIDIN1-YL-3-(PIPERIDIN-1-YL-CARBONYL)PYRAZINE-2-CARBOXAMIDE

The present invention relates to 5,6-bis(4-chlorophenyl)-N-piperidin1-yl-3-(piperidin-1-yl-carbonyl)pyrazine-2-carboxamide, to processes for preparing this compound, to its use in the treatment of obesity, psychiatric and neurological disorders, to methods for its therapeutic use and to pharmaceutical compositions containing it. The compound is a cannabinoid receptor 1 (CB1) modulator.

2,3-SUBSTITUTED 5,6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATORS

The present invention relates to 2,3-substituted 5,6-diaryl-pyrazine derivatives, e.g. 5,6-diaryl-3-heterocyclylpyrazine-2-ester derivatives of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them. The compounds are cannabinoid receptor 1 (CB1) modulators.

3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS

The present invention relates to 3-substituted-5,6-diarylpyrazine-2-carboxamide and -2-sulfonamide derivatives and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them. The compounds are cannabinoid receptor 1 (CB1) modulators.